Smith & Nephew (NYSE: SNN) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 30 (Q1), Smith & Nephew met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue was unchanged. Non-GAAP earnings per share dropped. GAAP earnings per share dropped.

Gross margins grew, operating margins dropped, net margins contracted.

Revenue details
 Smith & Nephew logged revenue of $1.08 billion. The six analysts polled by S&P Capital IQ predicted sales of $1.07 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.92. The four earnings estimates compiled by S&P Capital IQ anticipated $0.95 per share. Non-GAAP EPS of $0.92 for Q1 were 2.1% lower than the prior-year quarter's $0.94 per share. GAAP EPS of $0.16 for Q1 were 11% lower than the prior-year quarter's $0.18 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 75.0%, 10 basis points better than the prior-year quarter. Operating margin was 19.3%, 260 basis points worse than the prior-year quarter. Net margin was 13.3%, 160 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $1.09 billion. On the bottom line, the average EPS estimate is $0.96.

Next year's average estimate for revenue is $4.39 billion. The average EPS estimate is $3.78.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 112 members out of 122 rating the stock outperform, and 10 members rating it underperform. Among 32 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 29 give Smith & Nephew a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Smith & Nephew is hold, with an average price target of $57.56.

Is Smith & Nephew the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.